摘要
目的 探究丹参多酚酸联合双联抗血小板治疗非心源性急性非大面积脑梗死的临床效果及安全性.方法 选取2022 年2 月—2023 年3 月收治的60 例非心源性急性非大面积脑梗死,随机数字表法分为 2 组,每组 30例.对照组采取双联抗血小板治疗,观察组采取注射用丹参多酚酸盐联合双联抗血小板治疗.观察2 组临床疗效、不良反应,以及治疗前后纤维蛋白原(FIB)、凝血酶原时间(PT)、同型半胱氨酸(Hcy)、可溶性凋亡相关因子配体(sFasL)、抗凋亡因子(Livin)、可溶性凋亡相关因子(sFas)、脑血流灌注情况、Kelch样环氧氯丙胺相关蛋白1(Keap1)-核因子-E2 相关因子2(Nrf2)/抗氧化反应原件(ARE)信号通路[Keap1、Nrf2、醌氧化还原酶(NQO1)、ARE)]蛋白表达、美国国立卫生研究院卒中量表(NIHSS)、改良Rankin量表(mRS)评分.结果 观察组总有效率93.33%(28/30)高于对照组 73.33%(22/30)(P＜0.05).治疗 1、2 周后,观察组 FIB、Hcy、sFas、sFasL 以及 Keap1 蛋白表达低于对照组,PT长于对照组,Nrf2、NQO1、ARE蛋白表达以及Livin水平高于对照组,大脑前动脉、中动脉、后动脉血流速度较对照组快(P＜0.05).2 组不良反应发生总发生率比较,无显著差异(P＞0.05).治疗 2 周后及治疗后 3 个月,观察组mRS、NIHSS评分低于对照组(P＜0.05).结论 丹参多酚酸联合双联抗血小板治疗非心源性急性非大面积脑梗死效果确切,可通过调控凝血功能、脑微循环、Keap1-Nrf2/ARE信号通路而改善神经功能和预后,且具备一定安全性.
Abstract
Objective To explore the clinical efficacy and safety of Salvianolate(SAL)combined with dual anti-platelet therapy in the treatment of acute non-cardiogenic non-massive cerebral infarction.Methods Sixty patients with acute non-cardiogenic non-massive cerebral infarction treated from February 2022 to March 2023 were randomly divided into two groups,with 30 cases in each group,by random number table method.The control group was treated with dual antiplatelet therapy,and the observation group was treated with SAL for injection combined with dual antiplatelet therapy.The clinical ef-ficacy and adverse reactions of the two groups were observed.Fibrinogen(FIB),prothrombin time(PT),homocysteine(Hcy),soluble apoptosis-related factor ligand(sFasL),anti-apoptosis-related factor(Livin),soluble apoptosis-related factor(sFas),cerebral blood perfusion,Kelch-like epichloropropylamine associated protein 1(Keap1)-nuclear factor E2 associated factor2(Nrf2)/antioxidant component(ARE)signaling pathway[Keap1,Nrf2,quinone oxidoreductase(NQO1),ARE]protein expression,National Institutes of Health Stroke Scale(NIHSS)score,and Modified Rankin Scale(mRS)score before and after treatment were observed.Results The total effective rate of observation group was 93.33%(28/30),which was higher than that of control group[73.33%(22/30)](P＜0.05).At 1 and 2 weeks after treatment,the expression of FIB,Hcy,sFas,sFasL and Keap1 protein in observation group was lower than that in control group,the PT was longer than that in control group,the expression of Nrf2,NQO1,ARE protein and Livin level were higher than that in control group,and the blood flow velocity of anterior cerebral artery,middle artery and posterior artery was greater than that in control group(P＜0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P＞0.05).At 2 weeks and 3 months after treatment,mRS And NIHSS scores in the observation group were lower than those in the control group(P＜0.05).Conclusion SAL combined with dual antiplatelet therapy is effective in the treatment of acute non-cardiogenic non-massive cerebral infarction,and can improve nerve function and prognosis by regulating coagulation function,cerebral microcirculation,and Keap1-Nrf2/ARE signaling pathway,with certain safety.
国家科技期刊平台
NSTL
万方数据